Tag «amyotrophic lateral sclerosis»

Famlasertib

Famlasertib CAS 2375591-69-6 MFC26H27ClN4O MW 447.0 g/mol 4-[[4-[3-(3-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl]methyl]-1-piperazineethanol 2-[4-({4-[3-(3-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]phenyl}methyl)piperazin-1-yl]ethan-1-olserine/threonine kinase inhibitor, amyotrophic lateral sclerosis, Prosetin, WJP32276AY Prosetin is an orally administered blocker of MAP4K under investigation for the treatment of amyotrophic lateral sclerosis. Famlasertib (also known as Prosetin or Prostetin/12k) is a highly potent, small-molecule inhibitor targeting the mitogen-activated protein kinase kinase kinase kinase (MAP4K) family. …

ARIMOCLOMOL

ARIMOCLOMOL アリモクロモル; Formula C14H20ClN3O3 Exact mass 313.1193 Mol weight 313.7799 CAS 289893-25-0 289893-26-1 (Arimoclomol maleate); INN 8300 N-[(2R)-2-hydroxy-3-piperidin-1-ylpropoxy]-1-oxidopyridin-1-ium-3-carboximidoyl chloride BRX 220 FDA APPROVED, 9/20/2024, Miplyffa, To treat Niemann-Pick disease type C Press Release Drug Trials Snapshot Arimoclomol maleate is in a phase III clinical trials by Orphazyme for the treatment of Niemann-Pick disease type C (NP-C). …

Reldesemtiv

Reldesemtiv CK-2127107 CAS 1345410-31-2 UNII-4S0HBYW6QE, 4S0HBYW6QE MW 384.4 g/mol, MF C19H18F2N6O 1-[2-({[trans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methyl}amino)pyrimidin-5-yl]-1H-pyrrole-3- carboxamide 1-[2-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyrimidin-5-yl]pyrrole-3-carboxamide Reldesemtiv, also known as CK-2127107, is a skeletal muscle troponin activator (FSTA) and is a potential treatment for people living with debilitating diseases and conditions associated with neuromuscular or non-neuromuscular dysfunction, muscular weakness, and/or muscle fatigue such as SMA, COPD, and ALS. Cytokinetics , …

FDA approves drug to treat ALS, Radicava (Edaravone) , эдаравон, إيدارافون , 依达拉奉 ,ラジカット,

FDA approves drug to treat ALS 05/05/2017 The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease. May 5, 2017 Release The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly …